1486-P: Control of the Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in China—Results from iCaReMe China Registry

Introduction and Objective: The severe epidemic of Type 2 diabetes mellitus (T2DM) poses major global health threat in China. A comprehensive understanding of the current status of T2DM is paramount. In order to provide current and overall real-world data on clinical characteristics, treatment patterns and outcomes in patients with T2DM in China, we conducted iCaReMe China Registry. Methods: This is an ongoing prospective, multicentric, observational registry. Adult patients with T2DM were recruited from participating sites in China from July 2023 to March 2024. Consecutive patients attending the clinics for their routine health care visits were assessed for eligibility. The primary outcome is to describe the socio-demographic, clinical characteristics, disease management patterns, healthcare resource utilization, and clinical outcomes. Results: A total of 9,000 participants with T2DM (mean age 54.8±12.2 years old, mean diabetes duration 6.0±7.0 years) were enrolled from 60 hospitals in China. The mean level of HbA1c was 8.5±2.2%. 43.9%, 42.8%, and 10.7% of the patients reported comorbid hypertension, dyslipidemia, or chronic kidney disease. About 14.9% and 16.7% of them reported history of micro- and macro-vascular complications. 36.5%, 72.2%, and 36.1% of patients achieved the individual target goals for control of blood glucose (HbA1c<7%), blood pressure (SBP<130mmHg and DBP<80mmHg), and blood lipids (low density lipoprotein cholesterol<2.6mmol/L), respectively. Only 9.6% of patients achieved all 3 therapeutic targets. Conclusion: This study outlined the current status of glycemic control, blood pressure control, lipid control, and comorbidities in patients with T2DM in China, which suggesting urgent need of comprehensive management of diabetes. Adoption of cardiorenal protective therapies is crucial for optimization of clinical outcomes in patients with T2DM. Disclosure W. Yang: None. X. Cai: None. B. Feng: None. M. Liu: None. Y. Li: None. N. Tong: None. L. Ji: None.